High-sensitivity C-reactive protein and high mobility group box-1 levels in Parkinson's disease.
High mobility group box-1
High-sensitivity C-reactive protein
Inflammation
Parkinson’s disease
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
11
05
2018
accepted:
17
10
2018
pubmed:
26
10
2018
medline:
12
3
2019
entrez:
25
10
2018
Statut:
ppublish
Résumé
Various immunologic and inflammatory factors are contributed to pathogenesis of Parkinson's disease (PD). High mobility group box-1 (HMGB1) is a protein that plays certain roles in inflammation, DNA repair, transcription, somatic recombination, cell differentiation, cell migration, neuronal development, and neurodegeneration. The aim of the present study was to evaluate the serum levels of HMGB1 and high-sensitivity C-reactive protein (hs-CRP) among patients with Parkinson's disease and healthy controls. This study includes 30 patients with PD and 30 healthy controls, matched sex, age, body mass index, and smoking status. HMGB1 and hs-CRP serum levels were compared between the groups. The diagnostic performance of HMGB1 and hs-CRP was evaluated with receiver operating characteristic (ROC) curve analysis. HMGB1 levels were significantly higher in PD patients than in controls. Hs-CRP levels were significantly higher in PD patients than in controls There was a moderate correlation between hs-CRP and HMGB1 levels in the patient group. The cut-off value of HMGB1 level for the prediction of PD was determined as 32.8 ng/mL with 80% sensitivity and 60% specificity (p = 0.006). The cut-off value of hs-CRP level for the prediction of PD was determined as 0.63 mg/L with 66.7% sensitivity and 77.7% specificity (p = 0.007). This study demonstrates for the first time the association between HMGB1, hs-CRP, and PD. We found that HMGB1 and hs-CRP levels to be significantly higher in the PD patients than in the normal controls. As a result of the ROC curve analysis, HMGB1 and hs-CRP levels may be fair markers in the diagnosis of PD.
Identifiants
pubmed: 30353300
doi: 10.1007/s10072-018-3611-z
pii: 10.1007/s10072-018-3611-z
doi:
Substances chimiques
Biomarkers
0
HMGB1 Protein
0
HMGB1 protein, human
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
167-173Références
Trends Biochem Sci. 2001 Mar;26(3):167-74
pubmed: 11246022
EMBO J. 2001 Aug 15;20(16):4337-40
pubmed: 11500360
Am J Physiol Cell Physiol. 2003 Apr;284(4):C870-9
pubmed: 12620891
Neuroreport. 2004 Dec 22;15(18):2735-9
pubmed: 15597044
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
Lancet Neurol. 2005 Jun;4(6):371-80
pubmed: 15907742
J Neural Transm Suppl. 2006;(70):9-15
pubmed: 17017502
Nat Immunol. 2007 May;8(5):487-96
pubmed: 17417641
Cardiovasc Pathol. 2008 May-Jun;17(3):129-38
pubmed: 18402807
Nucleic Acids Res. 2009 Mar;37(4):1107-14
pubmed: 19129233
Lab Invest. 2009 Aug;89(8):948-59
pubmed: 19506549
Neurol Sci. 2011 Feb;32(1):31-4
pubmed: 20532580
J Neurosci. 2011 Jan 19;31(3):1081-92
pubmed: 21248133
J Dent Res. 2012 Feb;91(2):142-9
pubmed: 21876032
Mol Neurobiol. 2012 Jun;45(3):499-506
pubmed: 22580958
Oncol Lett. 2012 Jan;3(1):214-218
pubmed: 22740883
Intern Med. 2013;52(16):1787-92
pubmed: 23955613
ScientificWorldJournal. 2014 Jan 22;2014:121679
pubmed: 24587705
Mov Disord. 2014 Nov;29(13):1583-90
pubmed: 24976103
Biomed Res Int. 2014;2014:308654
pubmed: 25050341
Neurol Sci. 2015 Mar;36(3):423-8
pubmed: 25288159
Int J Neurosci. 2015;125(10):717-25
pubmed: 25364880
J Recept Signal Transduct Res. 2015;35(4):340-5
pubmed: 26482025
Exp Neurol. 2016 Jan;275 Pt 1:220-31
pubmed: 26555088
Neurobiol Dis. 2016 Jul;91:59-68
pubmed: 26921471
Brain Behav. 2018 Mar 25;8(4):e00948
pubmed: 29670828
Neurology. 1967 May;17(5):427-42
pubmed: 6067254